UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
WANG LABORATORIES, INC.
(Name of Issuer)
Common Stock, par value $.01
(Title of Class of Securities)
93369N109
(CUSIP Number)
Alan M. Stark
80 Main Street, West Orange, New Jersey 07052
(201) 325-8660
(Name, Address, and Telephone Number of Person Authorized
to Receive Notices and Communications)
July 26, 1995
(Date of Event which Requires Filing of this Statement)
If this filing person has previously filed a statement on Schedule
13G to report the acquisition which is the subject of this Schedule
13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4)
check the following box [ ].
Check the following box if a fee is being paid with this statement
[ ]. (A fee is not required only if the reporting person: (1) has
a previous statement on file reporting beneficial ownership of more
than five percent of the class of securities described in Item 1;
and (2) has filed no amendment subsequent thereto reporting
beneficial ownership of five percent or less of such class.) (See
Rule 13d-7.)
*The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect to the
subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a
prior cover page.
The information required on the remainder of this cover page shall
not be deemed to be "filed" for the purpose of Section 18 of the
Securities Exchange Act of 1934 ("Act") or otherwise subject to the
liabilities of that section of the Act but shall be subject to all
other provisions of the Act (however, see the Notes).<PAGE>
SCHEDULE 13D
CUSIP No. 93369N109
__________________________________________________________________
1) Names of Reporting Person S.S. or I.R.S. Identification
No. of Above Person
LEON G. COOPERMAN
S.S. No. ###-##-####
_________________________________________________________________
2) Check the Appropriate Box if a Member of a Group (See
Instructions)
(a) [ ]
(b) [ ]
_________________________________________________________________
3) SEC Use Only
_________________________________________________________________
4) Source of Funds:
WC
_________________________________________________________________
5) Check if Disclosure of Legal Proceedings is Required
Pursuant to Items 2(d) or 2(e). . . . . . . . . . . . .
N/A
_________________________________________________________________
6) Citizenship or place of Organization:
UNITED STATES
_________________________________________________________________
(7) Sole voting Power
Number of 2,375,087
Shares Bene- ____________________________________________________
ficially (8) Shared Voting Power
owned by 524,429
Each Report- ____________________________________________________
ing Person (9) Sole Dispositive Power
With 2,375,087
_________________________________________________________________
(10) Shared Dispositive Power
524,429
_________________________________________________________________
11) Aggregate Amount Beneficially Owned by Each Reporting
Person: 2,899,516
_________________________________________________________________
12) Check if the Aggregate Amount in Row (11) excludes
certain shares: N/A
_________________________________________________________________
13) Percent of Class Represented by Amount in Box (11):
8.6%
_________________________________________________________________
14) Type of Reporting Person
I N
Page 2 of 4 Pages<PAGE>
Item 3. Source and Amount of Funds or Other Consideration.
Cooperman beneficially owns 2,899,516 Shares. Of this
amount, 1,083,528 Shares were purchased on behalf of Omega Capital
Partners, L.P., at a cost of $8,661,351; 840,754 Shares were
purchased on behalf of Omega Institutional Partners, L.P., at a
cost of $6,762,280; 399,026 Shares were purchased on behalf of
Omega Overseas Partners, Ltd., at a cost of $2,687,163; 51,779
Shares were purchased on behalf of Omega Overseas Partners II,
Ltd., at a cost of $305,635; and 524,429 Shares were purchased on
behalf of the Managed Account at a cost of $5,371,692. The source
of funds for the purchase of all such Shares was investment
capital.
Item 5. Interest in Securities of the Issuer.
Based upon the information contained in the Company's
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission for the quarter ended March 31, 1995, there
were outstanding as of March 31, 1995 33,775,207 Shares. Omega
Capital Partners, L.P., owns 1,083,528 Shares, or 3.2% of those
outstanding; Omega Institutional Partners, L.P., owns 840,754
Shares, or 2.5% of those outstanding; Omega Overseas Partners,
Ltd., owns 399,026 Shares, or 1.2% of those outstanding; Omega
Overseas Partners II, Ltd., owns 51,779 Shares, or 0.2% of those
outstanding; and the Managed Account owns 524,429 Shares, or 1.6%
of those outstanding.
Page 3 of 4 Pages<PAGE>
The following table details the transactions by each of Omega
Capital Partners, L.P., Omega Institutional Partners, L.P., Omega
Overseas Partners, Ltd., Omega Overseas Partners II, Ltd., and the
Managed Account in the last 60 days. All of the transactions were
open market transactions.
OMEGA INSTITUTIONAL PARTNERS, L.P.
Date of Nature of Amount of Price Per
Transaction Transaction Shares Share
8/04/95 Sale 10,000 $ 18.25
8/04/95 Sale 75,000 18.00
MANAGED ACCOUNT
Date of Nature of Amount of Price Per
Transaction Transaction Shares Share
6/01/95 Sale 6,300 13.00
6/02/95 Sale 10,000 12.75
7/26/95 Sale 128,200 17.75
Signature
After reasonable inquiry and to the best of my knowledge
and belief, I certify that the information set forth in this state-
ment is true, complete and correct.
Dated: August 10, 1995
/s/ ALAN M. STARK
ALAN M. STARK on behalf of
LEON G. COOPERMAN, individually
and as managing partner of Omega
Capital Partners, L.P., and Omega
Institutional Partners, L.P., and as
President of Omega Advisors, Inc.
pursuant to Power of Attorney on file.
ATTENTION: INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACT
CONSTITUTE FEDERAL CRIMINAL VIOLATIONS (SEE 18 U.S.C. 1001).
Omega\Wang2.13D
Page 4 of 4 Pages
